Vineatrol and cardiovascular disease: beneficial effects of a vine-shoot phenolic extract in a hamster atherosclerosis model.
We evaluated the effect of the intake of a grapevine-shoot phenolic extract (Vineatrol 30) on early atherosclerosis in hamsters fed a hyperlipidic diet. Golden Syrian hamsters received for 13 weeks either a standard diet, a high-fat (HF) diet, or the HF diet plus Vineatrol 30 at 0.04, 0.2, or 1.0 mg/(kg body weight/d). We measured plasma lipids and glucose, insulin, leptin and adiponectin, as well as liver TNF-α and IL-6 levels. Oxidative stress was assessed by measuring plasma paraoxonase activity (PON) and liver superoxide anion production (O(2)(•-)). The aortic fatty streak area (AFSA) was also determined. In comparison with HF group, we demonstrated that the highest dose of Vineatrol 30 was capable of decreasing AFSA (67%), insulinemia (40%), and leptinemia (8.7%), which were increased by the HF diet. We also showed increased O(2)(•-) production (35%) and a rise in levels of the liver proinflammatory cytokines TNF-α (22%) and IL-6 (21%), accompanied by a fall in PON activity (56%) due to the HF diet versus the standard diet. In contrast, except plasma adiponectin levels that are not changed, Vineatrol 30 treatment lowered AFSA (67%), O(2)(•-) production (36%), insulin resistance (42%), leptinemia (9%), liver TNF-α (18%) and IL-6 (15%), while it rose PON activity (29%). These findings demonstrate the preventive effects of polyphenols present in Vineatrol 30 in managing cardiovascular, metabolic, and inflammatory risk factors.
Nutrition & Métabolisme, UMR 204 NUTRIPASS, Prévention des Malnutritions & des Pathologies Associées, Université Montpellier Sud de France, Place Eugène Bataillon, 34095 Montpellier, France.
Cindy
C
Romain
Sylvie
S
Gaillet
Julie
J
Carillon
Joris
J
Vidé
Jeanne
J
Ramos
Jean-Claude
JC
Izard
Jean-Paul
JP
Cristol
Jean-Max
JM
Rouanet
D052242:Adiponectin / Q000097:blood; D000818:Animals; D043303:Aryldialkylphosphatase / Q000097:blood; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D006224:Cricetinae; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008647:Mesocricetus; D018384:Oxidative Stress; D010636:Phenols / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D052242:Adiponectin; D001786:Blood Glucose; D007328:Insulin; D015850:Interleukin-6; D020738:Leptin; D008055:Lipids; D010636:Phenols; D014409:Tumor Necrosis Factor-alpha; C509818:vineatrol; D043303:Aryldialkylphosphatase